Role of 5 alpha-reductase inhibitors in the management of prostate cancer.

Steven J. Hudak, Javier Hernandez, Ian M. Thompson

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Prostate cancer is one of the most complex and enigmatic oncologic problems in medicine. It is highly prevalent, particularly in elderly males. Unfortunately, its generally protracted and variable clinical course and high association with treatment-related morbidity raise serious questions about the ideal treatment strategy for the individual patient. 5 alpha-reductase (5AR) inhibitors have a dramatic effect on benign prostatic disease with low toxicity. Thus, there is much interest in the potential role of 5AR inhibitors in the prevention and treatment of prostate cancer. Finasteride is the only agent that has been shown in a randomized clinical trial to decrease the risk of prostate cancer with a reduction of almost 25%. Additionally, a recent analysis of the Prostate Cancer Prevention Trial (PCPT) has found that finasteride improves the performance characteristics of prostate-specific antigen (PSA) blood test as a screening tool for prostate cancer, for both cancer detection as well as for detection of high risk disease. Finally, 5AR inhibitors have been studied as a component of multimodal therapy for all stages of prostate cancer, with the goal of improving oncologic outcomes while avoiding the toxicity of medical and surgical castration.

Original languageEnglish (US)
Pages (from-to)425-431
Number of pages7
JournalClinical Interventions in Aging
Volume1
Issue number4
DOIs
StatePublished - 2006

Fingerprint

5-alpha Reductase Inhibitors
Prostatic Neoplasms
Finasteride
Prostatic Diseases
Castration
Hematologic Tests
Therapeutics
Prostate-Specific Antigen
Randomized Controlled Trials
Medicine
Morbidity

ASJC Scopus subject areas

  • Geriatrics and Gerontology

Cite this

Role of 5 alpha-reductase inhibitors in the management of prostate cancer. / Hudak, Steven J.; Hernandez, Javier; Thompson, Ian M.

In: Clinical Interventions in Aging, Vol. 1, No. 4, 2006, p. 425-431.

Research output: Contribution to journalArticle

Hudak, Steven J. ; Hernandez, Javier ; Thompson, Ian M. / Role of 5 alpha-reductase inhibitors in the management of prostate cancer. In: Clinical Interventions in Aging. 2006 ; Vol. 1, No. 4. pp. 425-431.
@article{65b4d771d8bc454ab9cbcf5ce004cab8,
title = "Role of 5 alpha-reductase inhibitors in the management of prostate cancer.",
abstract = "Prostate cancer is one of the most complex and enigmatic oncologic problems in medicine. It is highly prevalent, particularly in elderly males. Unfortunately, its generally protracted and variable clinical course and high association with treatment-related morbidity raise serious questions about the ideal treatment strategy for the individual patient. 5 alpha-reductase (5AR) inhibitors have a dramatic effect on benign prostatic disease with low toxicity. Thus, there is much interest in the potential role of 5AR inhibitors in the prevention and treatment of prostate cancer. Finasteride is the only agent that has been shown in a randomized clinical trial to decrease the risk of prostate cancer with a reduction of almost 25{\%}. Additionally, a recent analysis of the Prostate Cancer Prevention Trial (PCPT) has found that finasteride improves the performance characteristics of prostate-specific antigen (PSA) blood test as a screening tool for prostate cancer, for both cancer detection as well as for detection of high risk disease. Finally, 5AR inhibitors have been studied as a component of multimodal therapy for all stages of prostate cancer, with the goal of improving oncologic outcomes while avoiding the toxicity of medical and surgical castration.",
author = "Hudak, {Steven J.} and Javier Hernandez and Thompson, {Ian M.}",
year = "2006",
doi = "10.2147/ciia.2006.1.4.425",
language = "English (US)",
volume = "1",
pages = "425--431",
journal = "Clinical Interventions in Aging",
issn = "1176-9092",
publisher = "Dove Medical Press Ltd.",
number = "4",

}

TY - JOUR

T1 - Role of 5 alpha-reductase inhibitors in the management of prostate cancer.

AU - Hudak, Steven J.

AU - Hernandez, Javier

AU - Thompson, Ian M.

PY - 2006

Y1 - 2006

N2 - Prostate cancer is one of the most complex and enigmatic oncologic problems in medicine. It is highly prevalent, particularly in elderly males. Unfortunately, its generally protracted and variable clinical course and high association with treatment-related morbidity raise serious questions about the ideal treatment strategy for the individual patient. 5 alpha-reductase (5AR) inhibitors have a dramatic effect on benign prostatic disease with low toxicity. Thus, there is much interest in the potential role of 5AR inhibitors in the prevention and treatment of prostate cancer. Finasteride is the only agent that has been shown in a randomized clinical trial to decrease the risk of prostate cancer with a reduction of almost 25%. Additionally, a recent analysis of the Prostate Cancer Prevention Trial (PCPT) has found that finasteride improves the performance characteristics of prostate-specific antigen (PSA) blood test as a screening tool for prostate cancer, for both cancer detection as well as for detection of high risk disease. Finally, 5AR inhibitors have been studied as a component of multimodal therapy for all stages of prostate cancer, with the goal of improving oncologic outcomes while avoiding the toxicity of medical and surgical castration.

AB - Prostate cancer is one of the most complex and enigmatic oncologic problems in medicine. It is highly prevalent, particularly in elderly males. Unfortunately, its generally protracted and variable clinical course and high association with treatment-related morbidity raise serious questions about the ideal treatment strategy for the individual patient. 5 alpha-reductase (5AR) inhibitors have a dramatic effect on benign prostatic disease with low toxicity. Thus, there is much interest in the potential role of 5AR inhibitors in the prevention and treatment of prostate cancer. Finasteride is the only agent that has been shown in a randomized clinical trial to decrease the risk of prostate cancer with a reduction of almost 25%. Additionally, a recent analysis of the Prostate Cancer Prevention Trial (PCPT) has found that finasteride improves the performance characteristics of prostate-specific antigen (PSA) blood test as a screening tool for prostate cancer, for both cancer detection as well as for detection of high risk disease. Finally, 5AR inhibitors have been studied as a component of multimodal therapy for all stages of prostate cancer, with the goal of improving oncologic outcomes while avoiding the toxicity of medical and surgical castration.

UR - http://www.scopus.com/inward/record.url?scp=38449104723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38449104723&partnerID=8YFLogxK

U2 - 10.2147/ciia.2006.1.4.425

DO - 10.2147/ciia.2006.1.4.425

M3 - Article

VL - 1

SP - 425

EP - 431

JO - Clinical Interventions in Aging

JF - Clinical Interventions in Aging

SN - 1176-9092

IS - 4

ER -